Strata Critical Medical, Inc. Q3 FY2024 earnings call

• Passenger: Had a strong summer season, particularly for Northeast leisure, drove Q3 2024 short distance revenue up. Exited the Western Canada market, and European operations were restructured to improve profitability.
• Medical: Saw a significant rebound in activity for October, achieved one of the highest monthly revenue levels. Formed a strategic alliance with OrganOx, expanded medical aircraft fleet, completed a tuck-in acquisition in medical to geographically expand the captive network of ground vehicles, and NRP adoption is increasing which is expected to drive more donor organs.

Passenger: Short distance revenue for Q3 2024 increased 6.5% year-over-year or 9.8% excluding Canada, while jet and other revenues declined 15% year-over-year. Passenger flight profit rose 31% year-over-year, passenger segment adjusted EBITDA doubled, and passenger segment adjusted EBITDA margin rose to 14.4% versus 7.3% in the prior year. Medical: Medical revenue rose 7.8% year-over-year to $36.1 million. Medical segment adjusted EBITDA improved 15.1% in Q3 2024 versus the prior year period, with margins expanding 70 basis points year-over-year despite a softer quarter for US organ transplant volumes.

• 2024 revenue guidance is between $240 million and $250 million with positive adjusted EBITDA. For 2025, passenger revenue is expected to be $85 million to $95 million, medical revenue to grow double digits year-over-year, and double digit adjusted EBITDA is expected. Also, positive free cash flow before aircraft acquisitions is anticipated barring large unforeseen non-recurring items.
• In Q4 2024, medical flight margin is expected to rebound to the low to mid 20% range, and passenger revenue in Q4 2024 is expected to be approximately $13 million.

• Quarter-to-quarter variability in the medical business due to the nonlinear growth of organ transplant volumes and associated unpredictability in timing of certain expenses and maintenance downtime. Also, dependence on strategic partnerships and fleet performance for continued growth and profitability.

Q: Jason Helfstein asked about Medical industry headwinds, aircraft downtime, and leveraging fleet for passengers.

A: William Heyburn and Robert Wiesenthal responded that there's quarter-to-quarter lumpiness due to various factors, flight profit per flight hour and per trip are growing, and there are opportunities to leverage fleet for passengers and other time-critical cargo.

Q: Lauren Lee asked about passenger segment 2025 guidance and Medical fleet strategy.

A: William Heyburn and Robert Wiesenthal explained that passenger guidance considers exiting Western Canada and continued single digit growth, while the Medical fleet strategy is economically beneficial with higher flight profit per trip and helps in winning new customers.

Q: Mahima Kakani asked about OrganOx partnership, passenger margins, and steady state assumptions.

A: Robert Wiesenthal responded that there's more demand for OrganOx's Metra Perfusion, passenger margins have room for expansion with strategies like fare classes, and there's continued margin expansion potential in passenger.

Q: Jon Hickman asked about passenger Q4 guidance.

A: William Heyburn stated that passenger Q4 2024 revenue is expected to be about $13 million, reflecting the Canada exit and continued single digit growth in short distance and flat jet and other revenue.

Q: Questions on vVTOL, flight margin path, medical competition, and capital allocation were asked.

A: Robert Wiesenthal and William Heyburn responded on vVTOL manufacturer relationships, flight margin expansion path, medical competition with NRP, and prudent capital allocation with focus on M&A and strategic investments.